GILD—In US market, Stribild is #1 HIV regimen and Complera is #2 regimen in all treatment settings. I.e. Atripla and PI-based regimens are all but obsolete. (Source: today’s CC.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”